US · CLPT
ClearPoint Neuro, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Solana Beach, CA 92075
- Website
- clearpointneuro.com
Price · as of 2024-12-31
$11.37
Market cap 373.94M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $36.69 | +222.69% |
| Intrinsic Value(DCF) | $5.54 | -51.28% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $62.40 | $797.87 | $1.05 | $0.00 | $0.00 |
| 2013 | $53.20 | $26.89 | $0.00 | $0.00 | $64.87 |
| 2014 | $33.20 | $89.42 | $0.00 | $0.00 | $0.00 |
| 2015 | $13.20 | $12.68 | $0.00 | $0.00 | $0.00 |
| 2016 | $4.60 | $166.23 | $0.59 | $0.00 | $0.00 |
| 2017 | $3.24 | $25.83 | $14.93 | $0.00 | $0.00 |
| 2018 | $3.25 | $37.56 | $0.00 | $0.00 | $0.00 |
| 2019 | $4.80 | $50.94 | $64.28 | $0.00 | $0.00 |
| 2020 | $20.25 | $43.67 | $2.57 | $0.00 | $0.00 |
| 2021 | $8.00 | $25.39 | $3.34 | $0.00 | $0.00 |
| 2022 | $7.95 | $27.19 | $1.83 | $0.00 | $0.00 |
| 2023 | $6.19 | $28.57 | $0.18 | $0.00 | $0.00 |
| 2024 | $13.07 | $36.69 | $3.57 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates ClearPoint Neuro, Inc.'s (CLPT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $36.69
- Current price
- $11.37
- AI upside
- +222.69%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.54
-51.28% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CLPT | ClearPoint Neuro, Inc. | $11.37 | 373.94M | +223% | -51% | — | — | -18.68 | 13.91 | 11.25 | -18.87 | — | 14.18 | 60.92% | -62.91% | -60.25% | -81.24% | -189.62% | -46.22% | 0.14 | — | 3.22 | 2.40 | 0.93 | -2222.00% | 3104.00% | -3610.00% | -2.61% | -0.86 | -88.59% | 0.00% | 0.00% | 2.08% | -17.05 | -36.50 | 10.73 | 8.37 |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | 347.63M | +2,616% | +600% | — | — | -60.62 | 9.94 | 1.37 | -56.76 | — | -12.26 | 83.29% | 9.95% | -2.26% | 64.49% | -72.80% | -1.79% | 0.00 | 0.97 | 1.13 | 1.42 | 75.38 | -9370.00% | 4746.00% | -26637.00% | 20.89% | 0.42 | -209.73% | 0.00% | 0.00% | 99.29% | 5.92 | 2.06 | 0.59 | -4.79 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| CMPS | COMPASS Pathways plc | $6.90 | 662.41M | — | — | — | — | -1.63 | 1.63 | — | -0.80 | — | 1.63 | 0.00% | — | — | -81.55% | -590.05% | -63.36% | 0.21 | -39.79 | 5.92 | 5.49 | 0.89 | -86.00% | — | 2231.00% | -47.22% | -3.50 | -394.64% | 0.00% | 0.00% | 0.00% | -0.67 | -1.00 | — | -2.75 |
| CTKB | Cytek Biosciences, Inc. | $4.48 | 572.83M | +597% | -46% | — | — | -8.51 | 1.66 | 2.81 | -18.31 | -0.83 | 1.84 | 51.84% | -20.04% | -33.02% | -18.05% | -35.25% | -13.85% | 0.04 | -85.20 | 5.04 | 4.16 | 4.42 | 102798.00% | 52.00% | -14013.00% | -1.55% | -0.06 | -7.65% | 0.00% | 0.00% | 0.00% | -7.88 | -36.31 | 1.58 | 3.49 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| OFIX | Orthofix Medical Inc. | $13.53 | 535.78M | +193% | -60% | — | — | — | 1.18 | 0.65 | -30.45 | — | 2.92 | 67.09% | -8.33% | -11.21% | 0.00% | -11.44% | 0.00% | 0.51 | -3.92 | 2.45 | 1.28 | -6.59 | -3091.00% | 285.00% | -8592.00% | -0.24% | 0.20 | -0.21% | 0.00% | — | 0.00% | -9.94 | -532.03 | 0.83 | 1.24 |
| SIBN | SI-BONE, Inc. | $15.52 | 673.43M | +222% | +44% | -88% | — | -36.13 | 3.85 | 3.40 | -49.18 | — | 3.85 | 79.57% | -11.11% | -9.41% | -10.97% | -52.40% | -8.06% | 0.01 | -4.23 | 8.55 | 7.03 | 3.77 | -4133.00% | 2019.00% | -6035.00% | -1.33% | -0.03 | -21.33% | 0.00% | 0.00% | 6.39% | -24.02 | -59.01 | 2.67 | 5.57 |
| SNDL | SNDL Inc. | $1.54 | 396.55M | +1,401% | +62% | -9% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
| SRDX | Surmodics, Inc. | $42.98 | 614.51M | +203% | -62% | -97% | — | -49.05 | 4.76 | 4.49 | 118.28 | -7.60 | 11.17 | 73.81% | -4.48% | -9.15% | -9.67% | -5.14% | -6.34% | 0.28 | -1.59 | 3.96 | 3.09 | -0.61 | 64545.00% | -491.00% | -14271.00% | -0.57% | 0.01 | -2.95% | 0.00% | 0.00% | 0.00% | -99.07 | -172.40 | 4.44 | 7.30 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
- CEO
- Joseph Michael Burnett
- Employees
- 115
- Beta
- 1.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.54 ÷ $11.37) − 1 = -51.28% (DCF, example).